Credit Suisse Neutral On Edwards Lifesciences

Credit Suisse is out with a research report on Edwards Lifesciences Corp. EW and it has a Neutral rating and a $99 price target on shares. In a note to clients, Credit Suisse writes, "Initiating at Neutral with a $99 price target: EW is a worldwide leader in the surgical and transcatheter aortic valve implant (TAVI) markets. While we expect strong TAVI growth to continue (we project 34% TAVI growth for EW and 33% market growth through 2015), we believe this growth is already reflected in EW's premium valuation, which drives our Neutral rating." Shares of EW closed at $89.69 yesterday.